New Report Highlights Dramatic Survival Gains and Persistent Barriers in SMA

The median age of diagnosis for spinal muscular atrophy in the United States has plummeted to just seven days, a sharp decline from over a year in 2017. As SMA Awareness Month begins, the organization Cure SMA reports this shift alongside a 60 percent drop in mortality rates over the last decade.

Corp and Tech·August 7, 2026·reads: 1,338

The 2025 State of SMA report, which draws on data from 11,000 individuals, credits the universal adoption of newborn screening in all 50 states for the accelerated timeline. Patients now typically receive their first treatment within 28 days of diagnosis, a massive improvement from the 196-day wait recorded eight years ago. Currently, 77 percent of the U.S. SMA community is utilizing FDA-approved therapies, contributing to a growing population of teenagers and adults living with the condition.

Despite these medical milestones, the community faces significant systemic and personal hurdles. Half of all patients report insurance denials for prescribed treatments or essential medical equipment like wheelchairs. Furthermore, the psychosocial burden remains high: 78 percent of adults indicate that the disease affects their mental health, with many expressing anxiety over the long-term efficacy of their medications and the potential loss of public benefits if their financial status changes through marriage. Cure SMA president Kenneth Hobby emphasized that while survival rates have improved, the organization’s focus is shifting toward the daily realities of fatigue and mental health, areas where current care still struggles to provide adequate support.